SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

VC-backed Achaogen debuts IPO

Achaogen has launched its IPO after pricing its 6 million shares at $12 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “AKAO.” Credit Suisse Securities and Cowen and Company are the lead underwriters. Based in South San Francisco, Achaogen is a biopharmaceutical company focused on developing antibiotics to treat bacterial infections. Its backers include 5AM Ventures, ARCH Venture Partners, Venrock, Versant Ventures, Frazier Healthcare Ventures, Domain Associates and Alta Partners.

SAGE Therapeutics secures $20m Series B financing

Biopharmaceutical company SAGE Therapeutics has secured a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011. The Series B financing will accelerate clinical and preclinical efforts to continue to advance SAGE’s pipeline programs in CNS disorders.

Siluria Technologies Appoints to Board

Siluria Technologies has appointed Karl Kurz to the company’s board of directors. Siluria is a company that converts natural gas into chemicals and fuels. It is backed by ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield & Byers, Bright Capital, Altitude Life Science Ventures, Lux Capital and Vulcan Capital.

Siluria Raises $30M From Bright, Vulcan, Kleiner, ARCH, Alloy, Others

Siluria Technologies said it closed a $30 million Series C financing led by new investors Bright Capital and Vulcan Capital and joined by existing investors ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield and Byers, Lux Capital, Altitude Life Science Ventures and Presidio Ventures. The company is developing a technology to convert […]

W Fund Officially Launches to Invest in Washington-Based Start-ups

Seattle-based W Fund, a $20 million, university-focused  fund that officially closed on May 31, officially launched today, according to its managing directors. The fund aims to back startups spun out of the University of Washington and other state research institution and its decisions will be made by an investment committee that Tom Alberg and Greg […]

Fate Therapeutics Appoints chairman and interim CEO

San Diego headquartered biotech company Fate Therapeutics has appointed William H. Rastetter as chairman and interim CEO. Rastetter is also a partner in venture capital firm Venrock. Fate Therapeutics has secured venture backing from OVP Venture Partners, Astellas Venture Management, Genzyme Ventures, ARCH Venture Partners, Polaris Venture Partners and Venrock. PRESS RELEASE Fate Therapeutics, Inc. […]

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups